GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &
GSK continued a run of several consecutive quarters of solid growth in the fourth quarter of 2022, helped by shingles vaccine Shingrix, but it needs to build up its pipeli
